Skip to content
DataLookout
Menu

NCT07711223

Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Phase changed: Phase 1/2 → Phase 3 Show 6 more changesShow less
    • Eligibility criteria shortened, about 7 words
    • Primary endpoints: details revised at 1 of 1 entry
    • Enrollment closed, study ongoing
    • Interventions: ACC017+FTC/TAF (Drug), DTG+FTC/TAF (Drug) to ACC017+FTC/TAF (Drug), DTG+FTC/TAF (Drug)
    • Secondary endpoints: details revised at 12 of 18 entries
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

At 48 weeks of treatment, the percentage of participants with HIV RNA load <50 copies/mL (analyzed using the US FDA Snapshot Approach) (primary analysis).
Timeframe: week 48

Secondary (18)

Percentage of participants with HIV RNA < LLOQ at Week 48;
Percentage of participants with HIV RNA <200 copies/mL at Week 48;
Percentage of participants with HIV RNA <50 copies/mL at Week 24;
Percentage of participants with HIV RNA < LLOQ at Week 24;
Absolute change from baseline in log10-transformed HIV RNA at Week 4;
Show 13 moreShow less
Absolute change from baseline in log10-transformed HIV RNA at Week 8;
Absolute change from baseline in log10-transformed HIV RNA at Week 12;
Percentage of participants with HIV RNA <50 copies/mL at Week 96 (final analysis);
Percentage of participants with HIV RNA < LLOQ at Week 96.
Absolute change from baseline in CD4+ cell count at Week 48 (cells/μL);
Percentage of participants with an increase from baseline in CD4+ cell count of ≥100 cells/μL or ≥30% at Week 48;
Absolute change from baseline in CD4+ cell count at Week 96 (cells/μL).
TEAEs (including ADRs, grade ≥3 AEs/ADRs, SAEs/SADRs, AEs/ADRs leading to treatment discontinuation/early trial withdrawal)
changes in vital signs
Number of Participants with Clinically Significant Abnormal Physical Examination Findings
Number of Participants with Clinically Significant QT Interval Prolongation on 12-Lead ECG
Number of Participants with Clinically Significant Laboratory Test Abnormalities
Number of Participants with Changes in Concomitant Medications

Arms and interventions

ACC017/FTC/TAFExperimental

stage 1:Participants receive ACC017 tablets plus emtricitabine/tenofovir alafenamide (FTC/TAF) tablets.

DTG/FTC/TAFActive comparator

stage1: Participants receive dolutegravir sodium tablets plus emtricitabine/tenofovir alafenamide (FTC/TAF) tablets.

Drugs: ACC017+FTC/TAF, DTG+FTC/TAF

Sites

1 site in 1 country

  • Beijing Ditan Hospital Capital Medical University, Beijing, ChinaBeijing, China